Associate Scientist II, Neuroscience at Axsome Therapeutics Inc

Mountain View, California, United States

Apply Now

Not SpecifiedCompensation

Junior (1 to 2 years), Mid-level (3 to 4 years)Experience Level

Full TimeJob Type

UnknownVisa

Biopharmaceutical, Rare DiseasesIndustries

Requirements

Bachelor’s degree in a Biology scientific discipline, preferably Biology, Neuroscience, or Immunology, with a minimum of 6 years’ experience, OR Master’s degree in a scientific discipline with a minimum of 2 years of relevant experience
Experience with multi-color flow cytometry and immunophenotyping primary human cells
Mammalian tissue culture experience with excellent sterile technique
Knowledge of basic Cell biology and Molecular biology
Exceptional attention to detail and time management skills
Strong analytical and problem-solving skills
Demonstrates technical proficiency and the ability to collaborate with others

Responsibilities

Under general guidance, executes experiments, interprets, and communicates results as part of multi-disciplinary team(s)
Applies relevant scientific principles and techniques to research problems
Maintains detailed laboratory notebooks
Maintains knowledge of state-of-the-art principles and techniques
Independently troubleshoots experiments, designing controls and generating interpretable data
Presents findings internally and contributes to the publication of the work of the project team
Contributes to the development of patent applications as appropriate
Complies with all safety requirements
Contributes to laboratory needs, such as stockroom maintenance and ordering supplies
Involved in general lab duties as assigned
Assists in target deconvolution studies using methodologies including flow cytometry, ELISA, Western blot, RT-qPCR
Executes weekly cell-based screening assays to support hit to lead optimization efforts for early-stage discovery programs
Maintains multiple cell lines (thawing, passaging, seeding) to support in vitro screening assays
Routinely uploads and reports data in a timely fashion, communicating any delays or changes in workflow to a cross-disciplinary team
Provides support for the design and optimization of new assays for the identification of additional hits
Profiles selected compounds to better understand compound mechanism of action in additional cells and tissues

Skills

Neuroscience

Drug Discovery

Scientific Experiments

Laboratory Techniques

Data Interpretation

Troubleshooting

Laboratory Notebooks

Scientific Principles

Axsome Therapeutics Inc

Develops therapies for CNS disorders

About Axsome Therapeutics Inc

Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, and Alzheimer's agitation. Their main product, AXS-05, is an oral medication that works by blocking NMDA receptors in the brain, which helps regulate mood. This drug has shown positive results in clinical trials and has received special FDA status to speed up its approval process. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous research and development. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these conditions.

New York City, New YorkHeadquarters

2012Year Founded

$430.7MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

201-500Employees

Benefits

Performance Bonus

Company Equity

Risks

Increased competition from companies like Compass Pathways in the CNS market.

Potential delays in AXS-07 launch amid growing market anticipation.

Departure of key personnel like Lori Englebert may impact strategic direction.

Differentiation

Axsome focuses on CNS disorders with limited current treatment options.

AXS-05, an NMDA receptor antagonist, targets major depressive disorder and treatment-resistant depression.

Axsome's balanced portfolio includes both clinical and research stage products.

Upsides

FDA's fast-tracking of CNS treatments could expedite Axsome's drug approvals.

Increased investment in CNS R&D drives innovation, benefiting Axsome's pipeline.

Growing personalized medicine trend offers Axsome opportunities for tailored therapies.

Land your dream remote job 3x faster with AI

Try Jobo Free